Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7241591, 6 pages
http://dx.doi.org/10.1155/2016/7241591
Review Article

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches

Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland

Received 8 September 2016; Accepted 5 October 2016

Academic Editor: Salah Aref

Copyright © 2016 Karl Haslam and Stephen E. Langabeer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Skoda, A. Duek, and J. Grisouard, “Pathogenesis of myeloproliferative neoplasms,” Experimental Hematology, vol. 43, no. 8, pp. 599–608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Langabeer, H. Andrikovics, J. Asp et al., “Molecular diagnostics of myeloproliferative neoplasms,” European Journal of Haematology, vol. 95, no. 4, pp. 270–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. H. L. Geyer and R. A. Mesa, “Emerging drugs for the treatment of myelofibrosis,” Expert Opinion on Emerging Drugs, vol. 20, no. 4, pp. 663–678, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Bench, H. E. White, L. Foroni et al., “Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations,” British Journal of Haematology, vol. 160, no. 1, pp. 25–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Z. Gong, J. R. Cook, T. C. Greiner et al., “Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the association for molecular pathology,” Journal of Molecular Diagnostics, vol. 15, no. 6, pp. 733–744, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Lippert, F. Girodon, E. Hammond et al., “Concordance of assays designed for the quantification of JAK2V617F: a multicenter study,” Haematologica, vol. 94, no. 1, pp. 38–45, 2009. View at Publisher · View at Google Scholar
  7. P. Collier, K. Patel, P. Waeltz et al., “Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples,” Genetic Testing and Molecular Biomarkers, vol. 17, no. 5, pp. 429–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Lippert, M. Boissinot, R. Kralovics et al., “The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera,” Blood, vol. 108, no. 6, pp. 1865–1867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. T. S. Larsen, J. H. Christensen, H. C. Hasselbalch, and N. Pallisgaard, “The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders,” British Journal of Haematology, vol. 136, no. 5, pp. 745–751, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. V. Jovanovic, A. Ivey, A. M. Vannucchi et al., “Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study,” Leukemia, vol. 27, no. 10, pp. 2032–2039, 2013. View at Publisher · View at Google Scholar
  11. A. Pancrazzi, P. Guglielmelli, V. Ponziani et al., “A sensitive detection method for MPL W515L or MPL W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction,” Journal of Molecular Diagnostics, vol. 10, no. 5, pp. 435–441, 2008. View at Google Scholar
  12. G.-R. Ruan, B. Jiang, L.-D. Li et al., “MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes,” Hematological Oncology, vol. 28, no. 1, pp. 33–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. L. V. Furtado, H. C. Weigelin, K. S. J. Elenitoba-Johnson, and B. L. Betz, “Detection of MPL mutations by a novel allele-specific PCR-based strategy,” Journal of Molecular Diagnostics, vol. 15, no. 6, pp. 810–818, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Zinke, V. Nageswaran, R. Reinhardt, and T. Burmeister, “Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR,” Molecular Diagnosis and Therapy, vol. 19, no. 5, pp. 329–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Girodon, C. Schaeffer, C. Cleyrat et al., “Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy,” Haematologica, vol. 93, no. 11, pp. 1723–1727, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Ricksten, L. Palmqvist, P. Johansson, and B. Andreasson, “Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia,” Haematologica, vol. 93, no. 8, pp. 1260–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Besses, A. Álvarez-Larrán, L. Martínez-Avilés et al., “Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients,” British Journal of Haematology, vol. 152, no. 4, pp. 413–419, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Theocharides, J. R. Passweg, M. Medinger et al., “The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders,” Haematologica, vol. 93, no. 12, pp. 1890–1893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. S. Larsen, N. Pallisgaard, K. de Stricker, M. B. Møller, and H. C. Hasselbalch, “Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden,” Hematology, vol. 14, no. 1, pp. 11–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Antonioli, A. Carobbio, L. Pieri et al., “Hydroxyurea does not appreciably reduce JAK2 v617F allele burden in patients with polycythemia vera or essential thrombocythemia,” Haematologica, vol. 95, no. 8, pp. 1435–1438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-J. Kiladjian, B. Cassinat, S. Chevret et al., “Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera,” Blood, vol. 112, no. 8, pp. 3065–3072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Quintás-Cardama, H. Kantarjian, T. Manshouri et al., “Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5418–5424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. T. S. Larsen, K. F. Iversen, E. Hansen et al., “Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha,” Leukemia Research, vol. 37, no. 9, pp. 1041–1045, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. T. S. Larsen, O. W. Bjerrum, N. Pallisgaard, M. T. Andersen, M. B. Møller, and H. C. Hasselbalch, “Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera,” Annals of Hematology, vol. 87, no. 10, pp. 847–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. T. Murphy, S. McPherson, and S. E. Langabeer, “Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha,” Annals of Hematology, vol. 90, no. 2, pp. 233–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Quintás-Cardama, O. Abdel-Wahab, T. Manshouri et al., “Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a,” Blood, vol. 122, no. 6, pp. 893–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. E. T. Kuriakose, S. Gjoni, Y. L. Wang et al., “JAK2 V617F allele burden is reduced by busulfan therapy: a new observation using an old drug,” Haematologica, vol. 98, no. 11, pp. e135–e137, 2013. View at Google Scholar
  28. C. Harrison, J.-J. Kiladjian, H. K. Al-Ali et al., “JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis,” The New England Journal of Medicine, vol. 366, no. 9, pp. 787–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Verstovsek, R. A. Mesa, J. Gotlib et al., “A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis,” The New England Journal of Medicine, vol. 366, no. 9, pp. 799–807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Deininger, J. Radich, T. C. Burn, R. Huber, D. Paranagama, and S. Verstovsek, “The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis,” Blood, vol. 126, no. 13, pp. 1551–1554, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Pieri, A. Pancrazzi, A. Pacilli et al., “JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib,” Blood, vol. 125, no. 21, pp. 3352–3353, 2015. View at Publisher · View at Google Scholar
  32. A. Koehler, K. Hubert, T. Lange et al., “JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib,” Annals of Hematology, vol. 94, no. 11, pp. 1929–1930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. N. M. Kröger, J. H. Deeg, E. Olavarria et al., “Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group,” Leukemia, vol. 29, no. 11, pp. 2126–2133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Kröger, A. Badbaran, E. Holler et al., “Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis,” Blood, vol. 109, no. 3, pp. 1316–1321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. N. K. Steckel, M. Koldehoff, M. Ditschkowski, D. W. Beelen, and A. H. Elmaagacli, “Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation,” Transplantation, vol. 83, no. 11, pp. 1518–1520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Alchalby, A. Badbaran, T. Zabelina et al., “Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis,” Blood, vol. 116, no. 18, pp. 3572–3581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Haslam, K. M. Molloy, E. Conneally, and S. E. Langabeer, “Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 3, pp. e29–e31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Benjamini, M. Koren-Michowitz, N. Amariglio, N. Kroger, A. Nagler, and A. Shimoni, “Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation,” Leukemia, vol. 22, no. 10, pp. 1961–1963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Kröger, H. Alchalby, E. Klyuchnikov et al., “JAK2-V617F triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation,” Blood, vol. 113, no. 8, pp. 1866–1868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Lange, A. Edelmann, U. Siebolts et al., “JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse,” Haematologica, vol. 98, no. 5, pp. 722–728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Carillo, L. Henry, E. Lippert et al., “Nested high-resolution melting curve analysis: a highly sensitive, reliable, and simple method for detection of Jak2 exon 12 mutations-clinical relevance in the monitoring of polycythemia,” Journal of Molecular Diagnostics, vol. 13, no. 3, pp. 263–270, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Kjær, M. Westman, C. H. Riley, E. Høgdall, O. W. Bjerrum, and H. Hasselbalch, “A highly sensitive quantitative real-time pcr assay for determination of mutant jak2 exon 12 allele burden,” PLoS ONE, vol. 7, no. 3, Article ID e33100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Ma, X. Zhang, X. Wang et al., “MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders,” Diagnostic Molecular Pathology, vol. 20, no. 1, pp. 34–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Rumi, F. Passamonti, L. Arcaini et al., “Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation,” Bone Marrow Transplantation, vol. 45, no. 4, pp. 798–800, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Alchalby, A. Badbaran, O. Bock et al., “Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT,” Bone Marrow Transplantation, vol. 45, no. 9, pp. 1404–1407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. G. M. Baerlocher, E. O. Leibundgut, O. G. Ottmann et al., “Telomerase inhibitor imetelstat in patients with essential thrombocythemia,” The New England Journal of Medicine, vol. 373, no. 10, pp. 920–928, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. A. V. Jones, D. Ward, M. Lyon et al., “Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms,” Leukemia Research, vol. 39, no. 1, pp. 82–87, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Klampfl, H. Gisslinger, A. S. Harutyunyan et al., “Somatic mutations of calreticulin in myeloproliferative neoplasms,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2379–2390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. Q.-M. Yao, J. Zhou, R. P. Gale et al., “A rapid, highly accurate method for quantifying calr mutant allele burden in persons with myeloproliferative neoplasms,” Hematology, vol. 20, no. 9, pp. 517–522, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Mehrotra, R. Luthra, R. R. Singh et al., “Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms,” American Journal of Clinical Pathology, vol. 144, no. 5, pp. 746–755, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Haslam, S. E. Langabeer, K. Molloy, M. F. Mcmullin, and E. Conneally, “Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation,” British Journal of Haematology, vol. 166, no. 5, pp. 800–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Verger, B. Cassinat, A. Chauveau et al., “Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations,” Blood, vol. 126, no. 24, pp. 2585–2591, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Guglielmelli, G. Rotunno, C. Bogani et al., “Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis,” British Journal of Haematology, vol. 173, no. 6, pp. 938–940, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Chi, M. Manoloukos, C. Pierides et al., “Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring,” Annals of Hematology, vol. 94, no. 3, pp. 399–408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. J. F. Huggett, S. Cowen, and C. A. Foy, “Considerations for digital PCR as an accurate molecular diagnostic tool,” Clinical Chemistry, vol. 61, no. 1, pp. 79–88, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Kinz, A. Leiherer, A. H. Lang, H. Drexel, and A. Muendlein, “Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR,” International Journal of Laboratory Hematology, vol. 37, no. 2, pp. 217–224, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Fontanelli, C. Baratè, E. Ciabatti et al., “Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2 (V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms,” International Journal of Laboratory Hematology, vol. 37, no. 6, pp. 766–773, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Waterhouse, M. Follo, D. Pfeifer et al., “Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR,” Annals of Hematology, vol. 95, no. 5, pp. 739–744, 2016. View at Publisher · View at Google Scholar
  59. O. Mansier, M. Migeon, A. Saint-Lézer et al., “Quantification of the mutant CALR allelic burden by digital PCR: application to minimal residual disease evaluation after bone marrow transplantation,” Journal of Molecular Diagnostics, vol. 18, no. 1, pp. 68–74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Badbaran, B. Fehse, M. Christopeit et al., “Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 51, no. 6, pp. 872–873, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Anelli, A. Zagaria, N. Coccaro et al., “Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms,” Annals of Hematology, vol. 95, no. 9, pp. 1559–1560, 2016. View at Publisher · View at Google Scholar
  62. P. Lundberg, A. Karow, R. Nienhold et al., “Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms,” Blood, vol. 123, no. 14, pp. 2220–2228, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. M. M. J. Kirschner, M. Schemionek, C. Schubert et al., “Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing,” PLoS ONE, vol. 10, no. 4, article e0123476, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Fu, T. Schroeder, T. Zabelina et al., “Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms,” European Journal of Haematology, vol. 92, no. 3, pp. 189–194, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Abdelhamid, M. Figeac, A. Renneville et al., “Quantification of JAK2V617F mutation by next-generation sequencing technology,” American Journal of Hematology, vol. 88, no. 6, pp. 536–537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Ostergaard, C. G. Nyvold, J. V. Jovanovic et al., “Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet,” Leukemia, vol. 25, no. 7, pp. 1168–1173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Barosi, A. Tefferi, C. Besses et al., “Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT),” Leukemia, vol. 29, no. 1, pp. 20–26, 2015. View at Publisher · View at Google Scholar · View at Scopus